Search

Displaying results 1811 - 1820 of 10000 in total
  1. Drug

    Dequalinium

    go.drugbank.com/drugs/DB04209
    Approved

    [A249255] First used as an antiseptic and disinfectant in the 1950s, dequalinium is still found in various OTC products to treat conditions of oral infections and inflammation. … [A249255] It is also used in vaginal tablets to treat bacterial vaginosis.[L42190]

  2. Drug

    Naxitamab

    go.drugbank.com/drugs/DB15965
    ApprovedInvestigational

    [L24454,A224604] Normally expressed during fetal development and in mature neurons, pain fibers, and skin cells, GD2 constitutes a highly efficient target in the treatment of neuroblastoma - it is widely … Naxitamab (humanized 3F8, hu3F8) is an IgG1 monoclonal antibody directed against the oncofetal differentiation antigen GD2 disialoganglioside.

  3. Drug

    Axicabtagene ciloleucel

    go.drugbank.com/drugs/DB13915
    ApprovedInvestigational

    Axicabtagene ciloleucel is an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. … [A216163] Axicabtagene ciloleucel was approved by the FDA on October 18th, 2017.

    Synonyms: Autologous T cells transduced with retroviral vector encoding an anti-CD-19 CD28/CD3-zeta chimeric antigen receptor
  4. Drug

    Loncastuximab tesirine

    go.drugbank.com/drugs/DB16222
    ApprovedInvestigational

    Zylonta also received approval in the EU on December 22, 2022. … [A234444] On April 23 2021, the Food and Drug Administration granted accelerated approval for the antibody-drug conjugate, loncastuximab tesirine-lpyl, also known as Zynlonta.

  5. Drug

    Prasugrel

    go.drugbank.com/drugs/DB06209
    ApprovedInvestigational

    FDA approved in 2009. … Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary

  6. Drug

    Sertindole

    go.drugbank.com/drugs/DB06144
    ApprovedWithdrawn

    It was first marketed in 1996 in several European countries before being withdrawn two years later because of numerous cardiac adverse effects. … It is a phenylindole derivative used in the treatment of schizophrenia.

  7. Drug

    Thonzonium

    go.drugbank.com/drugs/DB09552
    Approved

    It is also reported that thonzonium also confers an antifungal property and antiresorptive effect on bone. … It is widely used as an additive to in ear and nasal drops to enhance dispersion and penetration of cellular debris and exudate, thereby promoting tissue contact of the administered medication.

  8. Drug

    Carphenazine

    go.drugbank.com/drugs/DB01038
    ApprovedWithdrawn

    Carphenazine is an antipsychotic drug, used in hospitalized patients in the management of chronic schizophrenic psychoses.

  9. Drug

    Erythropoietin

    go.drugbank.com/drugs/DB00016
    ApprovedInvestigational

    Epoetin alfa (Epoge) was developed by Amgen Inc. in 1983 as the first rhEPO commercialized in the United States, followed by other alfa and beta formulations. … Erythropoietin (EPO) is a growth factor produced in the kidneys that stimulates the production of red blood cells.

    Products: EPORATIO 20000 I E /1ML, EPORATIO 1000 I E /0.5ML
  10. Drug

    Desflurane

    go.drugbank.com/drugs/DB01189
    ApprovedInvestigational

    It was developed in the late 1980s out of a need for a more rapidly acting and rapidly cleared inhaled anesthetic.[A226883,A226888] Desflurane was granted FDA approval on 18 September 1992.[L30285]